Celltrion, Institutional Investors Net Sell 95,453 Shares Over Last 5 Days... Stock Price at 238,000 KRW (+0.21%)

As of 12:31 PM on the 23rd, Celltrion is trading at 238,000 KRW, up 0.21% from the previous day. The trading volume is 508,803 shares, which is 63.42% of the previous day's volume. Celltrion is known as a protein and biopharmaceutical manufacturing company.

On October 20th, Kiwoom Securities researchers Hyemin Heo and Kyunghwan Kim stated, "The year-end announcement of Phase 2/3 Part 1 data for the COVID-19 treatment is highly anticipated, and based on the results, an application for emergency use authorization in Korea is expected. The preparation for initial large-scale commercial production and the commencement of Phase 2/3 clinical trials for the treatment under development indicate confidence in the product, which is positive. Additionally, the suspension of Eli Lilly's Phase 3 clinical trial for their COVID-19 antibody treatment suggests that Celltrion's treatment may take the lead, which is also positive." They set Celltrion's target price at 350,000 KRW.

Over the past five days, individual investors have net purchased 49,428 shares of Celltrion, while foreign investors and institutions have net purchased 30,439 shares and net sold 95,453 shares, respectively.

※ Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an automated article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.